Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Grazoprevir + Peg-IFN + RBV in HCV GT2/3
NCT01440595Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Nov 2011
- Primary completion
- May 2012
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of grazoprevir in hepatitis C (HCV), sponsored by Merck & Co.. Started Nov 2011; status: terminated.
02
Drugs
grazoprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01440595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01440595.